Shanghai Junshi Biosciences Co., Ltd. announced that the company has received the Acceptance Notice issued by the National Medical Products Administration. The investigational new drug application for WJ47156 tablets (project code: JS125) has been accepted. Relevant information is as follows: Drug name: WJ47156 tablets; Application matter: Clinical Trial of Domestic Production Registration of Pharmaceutical Product; Acceptance No.: CXHL2400678, CXHL2400680; Applicant: Shanghai Junshi Biosciences Co., Ltd.; Review conclusion: It is decided to be accepted upon review according to the requirements of Article 32 of the Administrative License Law of the People's Republic of China.

JS125 is a targeted histone deacetylases (HDACs) inhibitor, jointly developed by the company and Wigen Biomedicine Technology (Shanghai) Co., Ltd., and is intended for the treatment of malignant tumors, and belongs to the class of epigenetic modulator drugs. HDACs are involved in the regulation of the balance of acetylation and deacetylation of lysine residues of histones and non-histone proteins, and their expression is known to be closely associated with the occurrence and development of various malignant tumors. HDACs have multiple subtypes.

JS125 can selectively inhibit HDAC1, HDAC2 and HDAC3, and inhibit tumor by inducing cell cycle block, inhibiting angiogenesis, modulating immune response and promoting cancer cell senescence and apoptosis, thereby achieving the purpose of tumor treatment.